Physician profile
John C Mcduff
NPI 1467410530
$2,939.33
in general payments reported to CMS, 2019-2025
23 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $406 · 2021: $499 · 2022: $789 · 2023: $328 · 2024: $146 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $343.13 | 2021-2025 | |
| Pfizer INC. | $283.13 | 2019-2024 | |
| Lilly USA, LLC | $249.42 | 2019-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $245.86 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $174.18 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.42 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.24 | 2020-2021 | |
| Astellas Pharma US INC | $113.54 | 2019 | |
| Abbott Laboratories | $104.54 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $90.18 | 2019-2023 | Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $65.16 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $61.81 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $58.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $47.54 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $38.88 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.68 | 2021 | |
| Boston Scientific Corporation | $24.64 | 2025 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $23.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.00 | 2021 | |
| Corium, LLC | $17.37 | 2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $16.01 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcduff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.